Download PDF
Drug Res (Stuttg) 2016; 66(02): 69-73
DOI: 10.1055/s-0034-1398543
Original Article
© Georg Thieme Verlag KG Stuttgart · New York

Evaluation of Blood Alcohol Concentrations after Oral Administration of a Fixed Combination of Thyme Herb and Primrose Root Fluid Extract to Children with Acute Bronchitis

An Open-Label, Phase IV Clinical Trial
S. Ludwig
1   Paediatric Practice, Lübeck, Germany
,
H. Stier
2   Analyze & Realize GmbH, Berlin, Germany
,
S. Weykam
3   Cassella-med GmbH & Co. KG, Cologne, Germany
› Author Affiliations
Further Information

Publication History

received 27 August 2014

accepted 20 December 2014

Publication Date:
17 February 2015 (online)

Also available at
    Permissions and Reprints

Abstract

Background: The application of alcohol-containing medicinal products to children has been a subject of discussion for many years. A safety threshold of 0.125‰ blood alcohol concentration following the administration of a single dose has been recommended by the European Medicines Agency.

The aim of this clinical study was to prove the safety of administering a fixed combination of thyme herb and primrose root fluid extract (Bronchicum® Elixir) containing 4.9% ethanol.

Methods: The herbal drug was administered for a period of 7–9 days to 16 children (ages 1–12 years) suffering from acute bronchitis for≤48 h. After 3–5 days, a blood sample was taken 45 min (children≥5 years: also 0 and 90 min) after application of the drug. The efficacy was assessed using the Bronchitis Severity Score. Global efficacy and tolerability were rated by the investigator and patients.

Results: All measured blood ethanol concentrations were below the threshold (mean value after 45 min: 0.0029±0.0057‰ and after 90 min: 0.0051±0.0078‰). The Bronchitis Severity Score decreased from 6.6±1.0 to 0.9±1.6 points. Global efficacy was assessed as “very good” and “good” in 60% (investigator) and 80% (patients) of cases. Global tolerability was rated as “very good” and “good” in more than 90% of cases.

Conclusion: In conclusion, oral administration of the drug containing 4.9% ethanol to children (age 1–12 years) demonstrated a favourable risk/benefit ratio of the drug.

Key words

herbal medicinal product - ethanol - safety - threshold - clinical study - paediatric
 

  • References

  • 1 Grünwald J, Graubaum H-J, Busch R. Efficacy and Tolerability of a Fixed Combination of Thyme and Primrose Root in Patients with Acute Bronchitis. Drug Res 2005; 55: 669-676
    PubMedGoogle Scholar
  • 2 Grünwald J, Graubaum HJ, Busch R. Evaluation of the Non-inferiority of a Fixed Combination of Thyme Fluid and Primrose Root Extract in Comparison to a Fixed Combination of Thyme Fluid Extract and Primrose Root Tincture in Patients with Acute Bronchitis. Drug Res 2006; 56: 574-581
    PubMedGoogle Scholar
  • 3 Kelber O, Gaedke F, Steinhoff B et al. Ethanol in Herbal Medicinal Products for Children. Pharm Ind 2008; 70: 1124-1127
    PubMedGoogle Scholar
  • 4 Brand N. Alkohol in Arzneimitteln. Pflanzliche Liquida im Wandel – Sind die klassischen ethanolhaltigen Fluidextrakte und Tinkturen in Gefahr?. Deutsche Apoth Ztg 1996; 136: 251-258
    PubMedGoogle Scholar
  • 5 European Medicines Agency. Reflection paper on ethanol content in herbal medicinal products and traditional herbal medicinal products used in children. EMA/HMPC/85114/2008: 1–7
    PubMedGoogle Scholar
  • 6 American Academy of Pediatrics . Ethanol in Liquid Preparations Intended for Children. Pediatrics 1984; 73: 405
    PubMedGoogle Scholar
  • 7 Nahata MC. Safety of ‘‘inert’’ additives or excipients in paediatric medicines. Arch Dis Child Fetal Neonatal Ed 2009; 94: F392-F393
    CrossrefPubMedGoogle Scholar
  • 8 Spohr H-L, Willms J, Steinhausen H-C. Prenatal alcohol exposure and long-term developmental consequences. The Lancet 1993; 341 Jg., Nr. 8850, 907-910
    CrossrefPubMedGoogle Scholar
  • 9 Brown SA, McGue M, Maggs J et al. A developmental perspective on alcohol and youths 16 to 20 years of age. Pediatrics. 2008; 121: S290-S310
    PubMedGoogle Scholar
  • 10 ICH Harmonised tripartite guideline. Validation of analytical procedures: text and methodology Q2(R1). CPMP/ICH/381/95 1995
    PubMedGoogle Scholar
  • 11 Matthys H, Kamin W. Positioning of the Bronchitis Severity Score (BSS) for standardised use in clinical studies. Curr Med Res Opin 2013; 29: 1383-1390
    CrossrefPubMedGoogle Scholar
  • 12 Kardos P, Lehrl S, Kamin W et al. Assessment of the Effect of Pharmacotherapy in Common Cold/Acute Bronchitis – the Bronchitis Severity Scale (BSS). Pneumologie 2014; 68: 542-546
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 HMPC meeting report on community herbal monographs, guidelines and other activities. The 52nd HMPC meeting, held 13–14 May 2013
    PubMed
  • 14 Leung AK. Ethyl alcohol ingestion in children. A 15-year review. Clin Pediatr 1986; 25: 617-619
    CrossrefPubMedGoogle Scholar
  • 15 Norberg A, Jones AW, Hahn RG et al. Role of variability in explaining ethanol pharmacokinetics: research and forensic applications. Clin Pharmacokinet 2003; 42: 1-31
    CrossrefPubMedGoogle Scholar
  • 16 Nauert C, Eckert M. Fixe Kombination aus Thymian-Fluidextrakt und Primelwurzel-Fluidextrakt zur oralen Therapie von Kleinkindern und Kindern mit Husten und Bronchialkatarrh. Kongressband Phytopharmaka und Phytotherapie 2003; 130
    PubMedGoogle Scholar
  • 17 Nauert C, Grünwald J, Graubaum H-J. Wirksamkeit und Verträglichkeit flüssiger Darreichungsformen einer fixen Kombination von Thymian und Primula (T+P) bei Kindern mit akuter Bronchitis. Kongressband Phytopharmaka und Phytotherapie 2005; 31
    PubMedGoogle Scholar
  • 18 Nauert C. Nicht interventionelle Studie zeigt Effizienz bei Säuglingen. NaturaMed 2008; 1: 18-21
    PubMedGoogle Scholar
  • 19 Kelber O, Steinhoff B, Nauert C et al. Ethanol in Herbal Medicinal Products for Children: Study Data from 50,425 Children Support Safety. ICNPR 2012, New York, 29 July to 1 August 2012. Planta Med 2012; 78-PH19
    PubMedGoogle Scholar